<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218253</url>
  </required_header>
  <id_info>
    <org_study_id>20191226</org_study_id>
    <nct_id>NCT04218253</nct_id>
  </id_info>
  <brief_title>Clinical Application of Nutrition Support Package Before Hepatectomy</brief_title>
  <official_title>Clinical Application of Preoperative Nutritional Support Package for Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:To confirm the effect of preoperative oral nutrition therapy on patients with
      malnourished before liver cancer resection.

      Study design:Prospective, randomized, controlled clinical study. Primary end point: incidence
      of all complications 30 days after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complications at 30 days after surgery</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Postoperative complications were defined by Clavien-Dindo. Grade 1： Any deviation from the normal postoperative course without the need for pharmacologic treatment or surgical, endoscopic, and radiologic interventions. Allowed therapeutic regimens are drugs as antiemetics, antipyretics, analgetics, and diuretics, and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside.
Grade 2： Requiring pharmacologic treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.
Grade 3： Requiring surgical, endoscopic, or radiologic intervention 3a： Intervention not under general anesthesia 3b： Intervention under general anesthesia Grade 4：Life-threatening complication (including CNS complications) requiring IC/ICU management.
4a： Single organ dysfunction (including dialysis) 4b： Multiple organ dysfunction Grade 5： Death as a result of complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>from the date of the operation to the date of discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Neoplasms</condition>
  <condition>Nutrition Therapy</condition>
  <condition>Hepatectomy</condition>
  <arm_group>
    <arm_group_label>nutritional intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 or 500 calories nutritional support before operation according to the level of malnutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dietary education was conducted according to preoperative nutritional requirements</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber</intervention_name>
    <description>300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).</description>
    <arm_group_label>nutritional intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary mission</intervention_name>
    <description>Dietary education was conducted according to preoperative nutritional requirements</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>nutritional intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Clinical diagnosis of primary liver cancer (including hepatocellular carcinoma,
             bile duct carcinoma, and mixed cell carcinoma)

          -  2. No contraindications for surgery

          -  3. Eastern Cooperative Oncology Group (ECOG) score of preoperative physical state &lt;2
             points

          -  4. Preoperative liver function score Child-Pugh ≤ 6 points: total bilirubin ≤ 3.0 mg /
             dl, albumin ≥ 28 g / L, aspartate aminotransferase (AST), alanine aminotransferase
             (ALT), alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal

          -  5. Voluntarily enter the study and sign the informed consent form, and communicate
             well with the researcher

        Exclusion Criteria:

          -  1. Patients who took fish oil supplements within 3 weeks before the study began

          -  2. Patients with severe nutritional risk: serious nutritional risk should be
             considered when combining any of the following conditions: weight loss &gt; 10% within 6
             months; digital pain score (NRS) score &gt; 5 points; BMI &lt;18.5 kg/m2 (all patients with
             severe nutritional risk undergo individualized supportive care);

          -  3. Patients with malignant tumors in other parts

          -  4. Patients who are pregnant or lactating

          -  5. Patients with mental and neurological disorders who cannot cooperate with medical
             staff

          -  6. Patients with severe diabetes or poor glycemic control

          -  7. Patients cannot tolerate nutritional preparations

          -  8. Other circumstances that the researcher considers inappropriate to participate in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Wang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University cancer Instituteand Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunlei Li, Doctor</last_name>
    <phone>18622370261</phone>
    <email>lcltjmu507@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kun Wang, Doctor</last_name>
    <phone>23340123</phone>
    <phone_ext>1155</phone_ext>
    <email>lcltjmu507@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University cancer Instituteand Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Wang</last_name>
      <phone>23340123</phone>
      <phone_ext>1155</phone_ext>
      <email>lcltjmu507@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutrition Therapy</keyword>
  <keyword>Hepatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nutrients</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

